NASDAQ:PMN Promis Neurosciences (PMN) Stock Price, News & Analysis $0.55 +0.02 (+4.59%) Closing price 08/21/2025 04:00 PM EasternExtended Trading$0.54 -0.01 (-2.37%) As of 06:24 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Promis Neurosciences Stock (NASDAQ:PMN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Promis Neurosciences alerts:Sign Up Key Stats Today's Range$0.52▼$0.5550-Day Range$0.39▼$1.1252-Week Range$0.38▼$1.59Volume184,577 shsAverage Volume1.20 million shsMarket Capitalization$17.95 millionP/E RatioN/ADividend YieldN/APrice Target$4.33Consensus RatingBuy Company Overview ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada. Read More Promis Neurosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks61st Percentile Overall ScorePMN MarketRank™: Promis Neurosciences scored higher than 61% of companies evaluated by MarketBeat, and ranked 490th out of 937 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingPromis Neurosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoveragePromis Neurosciences has only been the subject of 2 research reports in the past 90 days.Read more about Promis Neurosciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Promis Neurosciences are expected to grow in the coming year, from ($0.24) to ($0.21) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Promis Neurosciences is -2.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Promis Neurosciences is -2.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.15% of the float of Promis Neurosciences has been sold short.Short Interest Ratio / Days to CoverPromis Neurosciences has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Promis Neurosciences has recently decreased by 72.15%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPromis Neurosciences does not currently pay a dividend.Dividend GrowthPromis Neurosciences does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.15% of the float of Promis Neurosciences has been sold short.Short Interest Ratio / Days to CoverPromis Neurosciences has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Promis Neurosciences has recently decreased by 72.15%, indicating that investor sentiment is improving significantly. News and Social Media2.2 / 5News SentimentN/A News SentimentPromis Neurosciences has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.Search InterestOnly 7 people have searched for PMN on MarketBeat in the last 30 days. This is a decrease of -56% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Promis Neurosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Promis Neurosciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.11% of the stock of Promis Neurosciences is held by insiders.Percentage Held by Institutions50.13% of the stock of Promis Neurosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Promis Neurosciences' insider trading history. Receive PMN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Promis Neurosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address PMN Stock News HeadlinesProMIS Neurosciences reports Q2 EPS (29c) vs (13c) last yearAugust 13, 2025 | msn.comProMIS Neurosciences Announces Second Quarter 2025 Financial Results & Corporate HighlightsAugust 13, 2025 | globenewswire.comThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 trillion vault of untapped American wealth. Former CIA advisor Jim Rickards calls it the “Old Testament Wealth Code” — and says it could transform your financial future. He’s revealing everything in a new presentation. | Paradigm Press (Ad)ProMIS Neurosciences to Showcase Protein-Misfolding Drug Discovery Platform & PRECISE-AD Trial Design at the 2025 Alzheimer's Association International ConferenceJuly 29, 2025 | globenewswire.comProMIS Neurosciences Announces Private Placement FinancingJuly 28, 2025 | globenewswire.comProMIS Neurosciences Announces Private Placement FinancingJuly 22, 2025 | globenewswire.comProMIS Neurosciences Granted Fast Track Designation by U.S. FDA for PMN310 in the Treatment of Alzheimer's DiseaseJuly 21, 2025 | globenewswire.comProMIS Neurosciences Granted Fast Track Designation by U.S. FDA for PMN310 in the Treatment of Alzheimer's DiseaseJuly 21, 2025 | globenewswire.comSee More Headlines PMN Stock Analysis - Frequently Asked Questions How have PMN shares performed this year? Promis Neurosciences' stock was trading at $0.9478 on January 1st, 2025. Since then, PMN shares have decreased by 42.1% and is now trading at $0.5490. How were Promis Neurosciences' earnings last quarter? Promis Neurosciences (NASDAQ:PMN) announced its quarterly earnings results on Wednesday, August, 13th. The company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.22) by $0.07. Who are Promis Neurosciences' major shareholders? Top institutional investors of Promis Neurosciences include Armistice Capital LLC (6.54%). Insiders that own company stock include Madge K Shafmaster, Patrick D Kirwin and Neil Cashman. View institutional ownership trends. How do I buy shares of Promis Neurosciences? Shares of PMN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Promis Neurosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Promis Neurosciences investors own include PayPal (PYPL), Recursion Pharmaceuticals (RXRX), Pacific Biosciences of California (PACB), Editas Medicine (EDIT), Exscientia (EXAI) and Trimble (TRMB). Company Calendar Last Earnings8/13/2025Today8/22/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PMN CIK1374339 Webwww.promisneurosciences.com Phone(416) 847-6898FaxN/AEmployees5Year FoundedN/APrice Target and Rating Average Price Target for Promis Neurosciences$4.33 High Price Target$6.00 Low Price Target$3.00 Potential Upside/Downside+689.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($0.21) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$2.78 million Net MarginsN/A Pretax MarginN/A Return on Equity-266.69% Return on Assets-131.59% Debt Debt-to-Equity RatioN/A Current Ratio0.97 Quick Ratio0.97 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.01) per share Price / Book-54.90Miscellaneous Outstanding Shares32,690,000Free Float30,692,000Market Cap$17.95 million OptionableNot Optionable Beta-0.04 Social Links 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:PMN) was last updated on 8/22/2025 by MarketBeat.com Staff From Our Partners[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredUS attacks China, September 30?The White House just ordered more than 400 government agencies to prepare for the next phase of America’s econ...Stansberry Research | SponsoredOne tiny company just cracked Google’s $19B problemGoogle’s AI-powered search could cost $20 billion a year in electricity—nearly half its profits. But new resea...True Market Insiders | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredI trusted Trump and got screwedPorter Stansberry says he got one thing wrong—and now millions of Americans could pay the price. After warning...Porter & Company | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Promis Neurosciences Please log in to your account or sign up in order to add this asset to your watchlist. Share Promis Neurosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.